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Human Immunodeficiency Virus Type 1 Entry into T Cells:
More-Rapid Escape from an Anti-V3 Loop Than
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The entry of human immunodeficiency virus type 1 into two T-cell lines has been analyzed to determine the
relative time courses with which virus entry can be blocked (i) by washing, (ii) by adding a monoclonal antibody
to the V3 loop of gpl20 that neutralizes without blocking CD4 binding (0.513), or (iii) by adding an antireceptor
monoclonal antibody that competes for virus binding (leu3a). During entry into C8166 cells, 50%o escape from
the wash as well as the anti-V3 loop antibody required 20 min, whereas 501% escape from the leu3a block
required 45 minutes. In contrast, during entry into H9 cells, 50%Yo escape from the wash block required 50 min,
50%Y escape from the anti-V3 loop antibody required 110 min, and 50%o escape from the antireceptor antibody
required 190 min. These results demonstrate that the times required for entering virus to escape each of the
blocks were cell type specific. They also demonstrate that V3 loop-dependent steps occur relatively early in
entry and suggest that binding of gp120 to CD4 is important for late as well as early steps in human
immunodeficiency virus type 1 entry.
Entry of human immunodeficiency virus type 1 (HIV-1)
into T cells is mediated by the viral envelope glycoproteins
gpl20 and gp4l and the CD4 host cell protein, which serves
as a receptor (for reviews, see references 7, 13, and 21).
HIV-1 envelope glycoproteins form the surface spikes visu-
alized in electron micrographs of virions. Each spike repre-
sents an oligomer of gpl20 and gp4l molecules (3). The gp4l
transmembrane proteins anchor the oligomer in the viral
membrane (5). Viral entry is mediated by gpl20 binding to
CD4 (for recent articles on this subject, see references 22
and 26), putative postbinding conformational changes that
expose a fusion domain at the N terminus of gp4l (2, 8, 9, 14,
19), and fusion of viral and host cell membranes. Entry is pH
independent and can occur by fusion through the cytoplas-
mic membrane or the membrane of an endocytic vesicle (6,
18, 20).
Recently, we used single-cycle analyses to demonstrate
that differences in the permissiveness of T-cell lines for
HIV-1 NL4-3 infections are determined by differences in the
permissiveness of the cells for virus entry (25). In the highly
permissive C8166 cells, 50% of the infectious units of NL4-3
escaped an antireceptor antibody block (leu3a block) within
approximately 30 min of infection. In contrast, in three less
permissive cell lines, H9, A3.01, and Jurkat, 50% entry
required an average of 4 h. Entry efficiency correlated with
entry rate, with stocks of NILA-3 having about three-times-
higher titers of infectious units on C8166 cells than on H9
cells. In each of the cell types, entry required CD4. How-
ever, the rate and efficiency of entry did not correlate with
surface levels of CD4.
The current study was undertaken to further characterize
steps that determine the rates with which infectious units of
NILA-3 enter cells. In particular, we wished to determine the
* Corresponding author.
relative time courses with which infectious units of NL4-3
escaped the ability to be blocked by the antireceptor mono-
clonal antibody leu3a and by a neutralizing monoclonal
antibody to the third variable (V3) loop of gpl20 (for a recent
article on this subject, see reference 15). Neutralizing anti-
body to the V3 loop does not block gpl2O-CD4 binding (23)
and is thought to act by inhibiting postbinding conforma-
tional changes that are required for entry. Studies of the time
course of NL4-3 escape from an anti-V3 loop antibody were
undertaken with C8166 and H9 cells. These two cell lines
have substantial differences in their permissiveness for
NLA-3 entry (25). A well-characterized neutralizing mono-
clonal antibody to the V3 loop, 0.5,B, was used to block V3
loop activity (17).
To establish conditions that would allow us to use 0.5,B as
an entry block, 0.51 concentrations of 0.02 to 20 ,ug/ml were
tested for their ability to block NL4-3 entry into C8166 and
H9 cells. Neutralization assays were conducted for NLA-3
that had been preincubated with 0.51 for 30 min at 37°C prior
to its addition to cells as well as for virus that was not
exposed to 0.51 until the time at which it was added to cells.
Several concentrations of leu3a were also tested for their
ability to block entry into C8166 and H9 cells. In these tests,
leu3a was added to cells 10 min before the addition of virus.
Both antibodies successfully blocked NL4-3 infections on
C8166 and H9 cells (Fig. 1). The concentration of 0.51
required to block entry was 100 to 1,000 times higher than
that of leu3a. The efficiency of the 0.51 block was not
affected by preincubating virus with antibody. Further
blocking experiments were done with 20 ,g of 0.513 per ml
and 250 ng of leu3a per ml. These levels of the two different
antibodies achieved .80% blocking of entry within 10 min
(Fig. 1). By working with levels of antibody that gave similar
levels of blocking, we minimized effects of differences in
affinity or binding kinetics on escape times.
The next series of experiments compared the time courses
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FIG. 1. Concentrations of the leu3a and 0.51 monoclonal an
bodies required to block entry of NL4-3 into C8166 (A) and H9 (
cells. The indicated concentrations of leu3a (0) were added to ce
10 min before the initiation of infections. The indicated concentr
tions of 0.51 were added to virus 30 min before infection (@) or
cells 10 min before infection (x). Percent entry is 100 times t]
number of cells that underwent infection in the presence of t]
blocking antibody divided by the number of cells that underwe
infection in the absence of the blocking antibody. See text f
details.
with which entry could be blocked by washing cells, t
adding the antireceptor antibody (leu3a block), or by addii
the anti-V3 loop neutralizing antibody (0.5,B block) (Fig.
and Table 1). Infections were initiated with prewarmed ce]
and virus in the presence of 2 ,ug of Polybrene per ml
multiplicities of 0.25 C8166 infectious units per cell.
various times postinfection, aliquots of infected cultur
underwent one of the blocking treatments (wash, addition
250 ng of leu3a per ml, or addition of 20 ,ug of 0.51 per m
At 12 to 15 h postinfection for H9 cells and 6 h for C81
cells, leu3a (250 ng/ml) and dideoxycytidine (2 ,uM) we
added to the cultures to prevent the spread of progeny viri
or syncytium formation, which would confuse the quantit
tion of the first round of infection (25). Successful entry w
scored by determining plateau levels of virus-expressir
cells by indirect immunofluorescence (assays were done >.
h after infection of C8166 cells and .65 h after infection
H9 cells) (25).
The time courses for escape from each of the blocks we
cell line specific (Fig. 2 and Table 1). The wash block, whi
measures the rate of virus adsorption to cells, was the fil
block to be passed, with infectious units requiring abo
three times longer to adsorb to H9 than to C8166 cell
Interestingly, in C8166 infections, escapes from the wa
and anti-V3 loop blocks had indistinguishable time courses.
This suggests that V3 loop-dependent steps in entry take
place essentially simultaneously with binding in C8166 cells.
In contrast, during entry into H9 cells, 50% escape from 0.51
required more than twice as long as escape from the wash.
Unexpectedly, in both C8166 and H9 cells, the leu3a escape
followed the 0.5,B escape. About 25 min elapsed between
escape from 0.51 and escape from leu3a in C8166 cells,
whereas about 80 min elapsed between these escapes in H9
cells.
To test whether the blocking pattern observed for 0.51
was a general pattern for anti-V3 loop antibodies, a poly-
clonal serum raised against a V3 loop peptide (RP135) in
)0 goats (10) was tested for its blocking activity. A 1:40 dilution
of this serum neutralized >95% of NL4-3 within 10 min. The
patterns of escape from the anti-RP135 serum were very
similar to those observed for 0.51 on both C8166 cells and
H9 cells (data not shown). As observed with 0.51, each of
the escapes preceded the leu3a escape. Thus, relatively
rapid escape from anti-V3 loop antibodies appears to be a
general characteristic of NL4-3 infections.
We had not anticipated that escape from the anti-V3 loop
antibodies would precede escape from leu3a. The relatively
rapid escape from the V3 loop blocks suggests that V3 loop
function in entry is early and short-lived. This could be
consistent with the hypothesis that proteolytic cleavage of
the V3 loop facilitates the exposure and function of the gp4l
fusion domain (2, 9, 11, 12). In contrast, the relatively long
)o periods required for leu3a escape suggest that late as well as
early steps in entry require binding of gpl20 to CD4.
ti- Quantitative analyses of the ability of synthetic soluble CD4
B) to block infectivity have demonstrated that multiple gpl20-
lls CD4 interactions are required for the entry of a single
ra- infectious unit (16). Our results suggest that these multiple
to interactions constitute a rate-limiting step in infection. One
he function of multiple gp120-CD4 binding events might be the
net triggering of conformational changes necessary for the fu-Fort sion step of entry. The enhancement of the infectivity of the
African green monkey simian immunodeficiency virus by
soluble CD4 would be consistent with this possibility (1). A
second explanation might be that fusion requires the recruit-
ment of the gp41 proteins present in several spikes into a
by single multimeric structure to form a fusion pore (24). Such
ng a multimeric structure would be consistent with the identi-
2 fication of a trans-dominant mutation in the fusion domain of
Ils gp4l (4).
at
At
es
of
1).
66
,re
us
ta-
as
ng
30
of
re
ch
rst
ut
Is.
,sh
We are grateful to E. Freed, N. Letvin, and P. Nara for discussion
and to C. Mulder for critical comments on the manuscript.
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TABLE 1. Times required for infectious units of NIA-3 to escape
various entry blocks in C8166 and H9 infections
Time required for 50% escape (min) ina:
Block
C8166 cells H9 cells
Wash 20 50
0.51 20 110
leu3a 45 190
a Data are taken from the time courses presented in Fig. 2. See text for
details.
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FIG. 2. Time courses with which infectious units of NL4-3 escaped various treatments. Shown are time courses for escape from the wash
block (x), the 0.5,B block (O and *), and the leu3a block (A and A) in C8166 cells (A) and H9 cells (B). (C) Data from panels A and B are
normalized for percent entry. The dashed lines indicate how the 50% escape times presented in Table 1 were estimated.
REFERENCES
1. Allan, J. S., J. Strauss, and D. W. Buck 1990. Enhancement of
SIV infection with soluble receptor molecules. Science 247:
1084-1088.
2. Clements, G. J., M. J. Price-Jones, P. E. Stephens, C. Sutton,
T. F. Schulz, P. R. Clapham, J. A. McKeating, M. 0. McClure,
S. Thomson, M. Marsh, J. Kay, R. A. Weiss, and J. P. Moore.
1991. The V3 loops of the HIV-1 and HIV-2 surface glycopro-
teins contain proteolytic cleavage sites: a possible function in
viral fusion? AIDS Res. Hum. Retroviruses 7:3-16.
3. Earl, P. L., R. W. Doms, and B. Moss. 1990. Oligomeric
structure of the human immunodeficiency virus type 1 envelope
glycoprotein. Proc. Natl. Acad. Sci. USA 87:648-652.
4. Freed, E. O., G. L. Buchschacher, Jr., E. L. Delwart, and A. T.
Panganiban. 1992. A mutation in the human immunodeficiency
virus type 1 transmembrane glycoprotein gp4l dominantly in-
terferes with fusion and infectivity. Proc. Natl. Acad. Sci. USA
89:70-74.
5. Gabuzda, D., U. Olshevsky, P. Bertani, W. A. Haseltine, and J.
Sodroski. 1991. Identification of membrane anchorage domains
of the HIV-1 gpl60 envelope glycoprotein precursor. J. Ac-
quired Immune Defic. Syndr. 4:34-40.
6. Grewe, C., A. Beck, and H. R. Gelderblom. 1990. HIV: early
virus-cell interactions. J. Acquired Immune Defic. Syndr.
3:965-974.
7. Habeshaw, J. A., A. G. Dalgleish, L. Bountiff, A. L. Newell, D.
Wilks, L. C. Walker, and F. Manca. 1990. AIDS pathogenesis:
HIV envelope and its interaction with cell proteins. Immunol.
Today 11:418-425.
8. Hart, T. K., R. Kirsch, H. Ellens, R. W. Sweet, D. M. Lambert,
S. R. Petteway, Jr., J. Leary, and P. J. Bugelski. 1991. Binding
of soluble CD4 proteins to human immunodeficiency virus type
1 and infected cells induces release of envelope glycoprotein
gpl20. Proc. Natl. Acad. Sci. USA 88:2189-2193.
9. Hattori, T., A. Koito, K. Takatsuki, H. Kido, and N. Katunuma.
1989. Involvement of tryptase-related cellular protease(s) in
human immunodeficiency virus type 1 infection. FEBS Lett.
248:48-52.
10. Javaherian, K., A. J. Langlois, C. McDanal, K. L. Ross, L. I.
Eckler, C. L. Jellis, A. T. Profy, J. R. Rusche, D. P. Bolognesi,
S. D. Putney, and T. J. Matthews. 1989. Principal neutralizing
domain of the human immunodeficiency virus type 1 envelope
glycoprotein. Proc. Natl. Acad. Sci. USA 86:6768-6772.
11. Kido, H., A. Fukutomi, and N. Katunuma. 1990. A novel
membrane-bound serine esterase in human T4+ lymphocytes
immunologically reactive with antibody inhibiting syncytia in-
duced by HIV-1. J. Biol. Chem. 265:21979-21985.
12. Kido, H., A. Fukutomi, and N. Katunuma. 1991. Tryptase TL-2
in the membrane of human T4+ lymphocytes is a novel binding
protein of the V3 domain of HIV-1 envelope glycoprotein gpl20.
FEBS Lett. 286:233-236.
13. Kieber-Emmons, T., B. A. Jameson, and W. J. Morrow. 1989.
The gpl2O-CD4 interface: structural, immunological and patho-
logical considerations. Biochim. Biophys. Acta 989:281-300.
14. Kowalski, M., J. Potz, L. Basiripour, T. Dorfman, W. C. Goh, E.
Terwilliger, A. Dayton, C. Rosen, W. Haseltine, and J. Sodroski.
1987. Functional regions of the envelope glycoprotein of human
immunodeficiency virus type 1. Science 237:1351-1355.
15. LaRosa, G. J., J. P. Davide, K. Weinhold, J. A. Waterbury,
A. T. Profy, J. A. Lewis, A. J. Langlois, G. R. Dreesman, R. N.
Boswell, P. Shadduck, L. H. Holley, M. Karplus, D. P. Bolognesi,
T. J. Matthews, E. A. Emini, and S. D. Putney. 1990. Conserved
sequence and structural elements in the HIV-1 principal neu-
tralizing determinant. Science 249:932-935.
16. Layne, S. P., M. J. Merges, M. Dembo, J. L. Spouge, and P. L.
Nara. 1990. HIV requires multiple gpl20 molecules for CD4-
A
a
=
c
la
0
-
oI-
5 . . .
5 6 7
VOL. 66, 1992
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
2550 NOTES
mediated infection. Nature (London) 346:277-279.
17. Matsushita, S., M. Robert-Guroff, J. Rusche, A. Koito, T.
Hattori, H. Hoshino, K. Javaherian, K. Takatsuki, and S.
Putney. 1988. Characterization of a human immunodeficiency
virus neutralizing monoclonal antibody and mapping of the
neutralizing epitope. J. Virol. 62:2107-2114.
18. McClure, M. O., M. Marsh, and R. A. Weiss. 1988. Human
immunodeficiency virus infection of CD4-bearing cells occurs
by a pH-independent mechanism. EMBO J. 7:513-518.
19. Moore, J. P., J. A. McKeating, W. A. Norton, and Q. J.
Sattentau. 1991. Direct measurement of soluble CD4 binding to
human immunodeficiency virus type 1 virions: gpl20 dissocia-
tion and its implications for virus-cell binding and fusion reac-
tions and their neutralization by soluble CD4. J. Virol. 65:1133-
1140.
20. Pauza, C. D., and T. M. Price. 1988. HIV infection of T cells and
monocytes proceeds via receptor mediated endocytosis. J. Cell
Biol. 107:959-968.
21. Putney, S. D., J. Rusche, K. Javaherian, T. Matthews, and D.
Bolognesi. 1990. Structural and functional features of the HIV
envelope glycoprotein and considerations for vaccine develop-
ment. BiotTechnology 14:81-110.
22. Ryu, S.-E., P. D. Kwong, A. Truneh, T. G. Porter, J. Arthos, M.
Rosenberg, X. Dai, N.-H. Xoung, R. Axel, R. W. Sweet, and
W. A. Hendrickson. 1990. Crystal structure of an HIV-binding
recombinant fragment of human CD4. Nature (London) 348:
419-425.
23. Skinner, M. A., A. J. Langlois, C. B. McDanal, J. S. McDougal,
D. P. Bolognesi, and T. J. Matthews. 1988. Neutralizing antibod-
ies to an immunodominant envelope sequence do not prevent
gpl20 binding to CD4. J. Virol. 62:4195-4200.
24. Spruce, A. E., A. Iwata, J. M. White, and W. Almers. 1989.
Patch clamp studies of single cell-fusion events mediated by a
viral fusion protein. Nature (London) 342:555-558.
25. Srivastava, K. K., R. Fernandez-Larsson, D. M. Zinkus, and
H. L. Robinson. 1991. Human immunodeficiency virus type 1
NL4-3 replication in four T-cell lines: rate and efficiency of
entry, a major determinant of permissiveness. J. Virol. 65:3900-
3902.
26. Wang, J., Y. Yan, T. P. J. Garrett, J. Liu, D. W. Rodgers, R. L.
Garlick, G. E. Tarr, Y. Husain, E. L. Reinherz, and S. C.
Harrison. 1990. Atomic structure of a fragment of human CD4
containing two immunoglobulin-like domains. Nature (London)
348:411-418.
J. VIROL.
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
